Syndax Pharmaceuticals, Inc. (SNDX)

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences: TD Cowen 46th Annual Health Care Conference in Boston, MA, with a fireside chat on Monday, March 2, 2026, at 1:50 p.m.

NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its fourth quarter and full year 2025 financial results and provide a business update on Thursday, February 26, 2026. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m.

Syndax Pharmaceuticals (SNDX) demonstrates strong commercial momentum with Revuforj and Niktimvo, driving notable revenue growth post-FDA approvals. Revuforj's 4Q25 net revenue surged 38% QoQ to $44M, while Niktimvo delivered $56M, underscoring robust adoption in underserved patient populations. SNDX maintains a solid $394M cash position, supporting ongoing clinical trials and pipeline expansion, though competition from Komzifti introduces new risks.

Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX - Get Free Report) CFO Keith Goldan sold 2,082 shares of the company's stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $20.62, for a total transaction of $42,930.84. Following the completion of the sale, the chief financial officer directly owned

NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will participate in a fireside chat at the 2026 Guggenheim Emerging Outlook: Biotech Summit on Thursday, February 12, 2026, at 12:30 p.m.

NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on February 1, 2026, the Company granted inducement awards to purchase up to 11,600 shares of common stock to two new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.

Syndax Pharmaceuticals, Inc. (SNDX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

– Approximately $44 million and $125 million in preliminary (unaudited) Revuforj ® (revumenib) 4Q25 and full year 2025 net revenue, respectively –  – Continued acceleration in demand following approval in R/R NPM1m AML, with an approximate 38% increase in Revuforj net revenue in 4Q25 vs. 3Q25 -  – $56 million and $152 million in preliminary (unaudited) Niktimvo™ (axatilimab-csfr) 4Q25 and full year 2025 net revenue, respectively; Syndax will report its share of the Niktimvo net profit when it reports full year 2025 results –  – Ended 2025 with approximately $394 million in cash, cash equivalents and marketable securities (unaudited); fully funded through profitability –  – Syndax to present at the 44 th Annual J.P.

- Program will expand access in certain regions where Revuforj is not available commercially, as permitted by local regulations - - Program will be launched in parts of Eurasia, Central and Southeast Europe, Israel, the Middle East and Turkey, Latin America, and Africa - NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX) and the World Orphan Drug Alliance (WODA) today announced a collaboration to expand access to the Company's first-in-class menin inhibitor, Revuforj® (revumenib), through a Managed Access Program. This program enables physicians to prescribe Revuforj to appropriate patients outside the U.S. where the drug is not approved but access to novel medicines is permitted by local regulations and where funding can be secured.

Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX - Get Free Report) has earned a consensus rating of "Moderate Buy" from the twelve research firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, nine have given a buy recommendation and one

NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 3:00 p.m. PT/ 6:00 p.m. ET.

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX - Get Free Report) reached a new 52-week high on Tuesday. The stock traded as high as $21.50 and last traded at $21.48, with a volume of 1371684 shares traded. The stock had previously closed at $20.77. Wall Street Analysts Forecast Growth SNDX has been the topic of

Syndax Pharmaceuticals is now a commercial-stage biopharma with two FDA-approved drugs: Revuforj and Niktimvo. SNDX's Revuforj leads in efficacy for AML, with rapid market penetration and a first-mover advantage in front-line Phase 3 trials. Despite cardiac risk concerns, lower-dose combination data suggest manageable safety, supporting SNDX's strong buy rating.

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj® (revumenib) was named Best New Drug at the Scrip Awards 2025, held by Citeline. The Best New Drug Award recognizes excellence in pharmaceutical development and the drug that represents the best therapeutic advance in its area.

Syndax Pharmaceuticals, Inc. (SNDX) Presents at The 67th American Society of Hematology (ASH) Annual Meeting Transcript

Stock News China's trade surplus tops $1T YTD: China's exports rose 5.9% in November while imports grew 1.9%, pushing the 11‑month surplus to nearly $1.08 tri